AtriCure offers unique technologies for the treatment of persistent atrial fibrillation - Needham sees 25% upside potential!
Reading Time: 2 minutes
The medical technology company AtriCure (ATRC) specializes in the treatment of atrial fibrillation (Afib) and offers the Isolator Synergy Ablation System, the only FDA-approved surgical ablation device for the treatment of persistent atrial fibrillation. With its complete product portfolio for surgeries and pain relief, it targets a market worth 10 billion USD worldwide. Currently, approximately 59 million people are affected by atrial fibrillation (Afib) globally. AtriCure surprised on January 13th with a 17% increase in revenue for the 4th...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
